

CATALYST PHARMACEUTICAL PARTNERS, INC.  
Form 8-K  
August 29, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of Earliest Event Reported): August 28, 2013**

**CATALYST PHARMACEUTICAL**  
**PARTNERS, INC.**  
**(Exact Name Of Registrant As Specified In Its Charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**001-33057**  
**(Commission**  
**File Number)**

**76-0837053**  
**(I.R.S. Employer**  
**Identification No.)**

**355 Alhambra Circle**

**Suite 1500**

**Coral Gables, Florida**  
**(Address of principal executive offices)**

**33134**  
**(Zip Code)**

**Registrant's telephone number, including area code: (305) 529-2522**

**Not Applicable**

**Former Name or Former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On August 28, 2013, Catalyst Pharmaceutical Partners, Inc. ( Company ) and its Chairman, President and Chief Executive Officer, Patrick J. McEnany, entered into an amendment to Mr. McEnany s employment agreement with the Company extending the term of such agreement for an additional three year period. Mr. McEnany s employment agreement with the Company now expires on November 8, 2016. All of the other terms of Mr. McEnany s employment agreement with the Company remain the same.

A copy of Amendment No. 4 to Mr. McEnany s employment agreement with the Company is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The description of Amendment No. 4 that is set forth above is qualified in its entirety by reference to such amendment.

**Item 8.01 Other Events**

On August 28, 2013, the Company received approximately \$1,378,000 upon the exercise of common stock purchase warrants to purchase an aggregate of 1,297,500 shares of the Company s common stock. A portion of the warrants that were exercised were originally issued in the Company s October 2011 registered direct offering, and the balance of the warrants that were exercised were issued in the Company s May 2012 public offering. The shares of common stock issued upon the exercise of these warrants are fully registered under the Securities Act of 1933.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

- 10.1 Amendment No. 4 to Employment Agreement between the Company and Patrick J. McEnany, dated August 28, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceutical Partners, Inc.**

By: /s/ Alicia Grande  
Alicia Grande  
Vice President, Treasurer and CFO

Dated: August 28, 2013